Antibiotic Management Strategies for Necrotizing Soft Tissue Infections

Overview

Necrotizing soft tissue infections (NSTIs) are severe, rapidly progressing infections requiring urgent broad-spectrum antibiotic therapy combined with surgical debridement. The Greater Paris SURFAST Consortium developed consensus recommendations to standardize antibiotic management based on risk factors for resistant organisms and clinical severity.

Background

NSTIs are rare but life-threatening infections characterized by extensive necrosis of skin and subcutaneous tissues, most commonly affecting the lower extremities. They often occur in patients with comorbidities such as diabetes, obesity, and immunosuppression, and can be polymicrobial or monomicrobial, with Streptococcus pyogenes being a common pathogen. Mortality rates range from 10% to 30%, and survivors frequently experience significant morbidity. Urgent management includes broad-spectrum antibiotics, surgical debridement, and intensive care support, but antibiotic regimens vary widely due to limited high-quality evidence.

Data Highlights

The SURFAST consortium identified key risk factors for infections with extended spectrum β-lactamase-producing Enterobacterales (ESBL-E) and methicillin-resistant Staphylococcus aureus (MRSA), guiding empiric antibiotic choices. ESBL-E risk factors include recent hospitalization, prior antibiotic exposure, colonization, and travel to endemic regions. MRSA risk factors include residency in care facilities, immunosuppression, recent antibiotic exposure, and specific community settings. Empiric carbapenem use is reserved for patients with multiple risk factors and severe disease, while anti-MRSA coverage is recommended in high endemicity settings and pediatric populations.

Key Findings

• NSTIs require immediate initiation of broad-spectrum intravenous antibiotics combined with rapid surgical debridement.
• Risk stratification for ESBL-E and MRSA infections is critical to guide empiric antibiotic therapy.
• ESBL-E risk factors include recent hospitalization, antibiotic exposure, colonization, and travel to endemic areas; empiric carbapenems should not be used based on a single risk factor alone.
• MRSA risk factors include residence in post-acute care, immunosuppression, recent antibiotic use, and specific community exposures; anti-MRSA coverage is warranted in high endemicity settings and pediatric cases.
• Severe β-lactam allergies necessitate alternative antibiotic regimens avoiding β-lactams.
• Sepsis and septic shock definitions guide clinical severity assessment and influence antibiotic management decisions.

Clinical Implications

Clinicians should assess individual patient risk factors for resistant organisms to tailor empiric antibiotic therapy appropriately in NSTIs. Broad-spectrum coverage should be initiated promptly, with adjustments based on microbiological data and clinical response. Avoiding unnecessary carbapenem use helps prevent resistance development, and anti-MRSA coverage should be considered in high-risk populations, including children.

Conclusion

The SURFAST consortium provides a multidisciplinary consensus framework to optimize antibiotic management in NSTIs, emphasizing risk-based empiric therapy combined with urgent surgical intervention. This approach aims to improve outcomes by balancing effective coverage with antimicrobial stewardship.

References

1. Greater Paris SURFAST Consortium -- Antibiotic Management Strategies for Necrotizing Soft Tissue Infections